Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer

Brachytherapy ◽  
2006 ◽  
Vol 5 (3) ◽  
pp. 157-164 ◽  
Author(s):  
Yoshiya Yamada ◽  
Sudershan Bhatia ◽  
Marco Zaider ◽  
Gilad Cohen ◽  
Machele Donat ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Dose Rate ◽  
Clinical Outcomes ◽  
Three Dimensional ◽  
High Dose Rate ◽  
Localized Prostate Cancer ◽  
High Dose ◽  
Prostate Brachytherapy

scholarly journals High-Dose-Rate Brachytherapy in the Curative Treatment of Patients With Localized Prostate Cancer

2008 ◽  
Vol 83 (12) ◽  
pp. 1364-1372 ◽  
Author(s):  
Thomas M. Pisansky ◽  
Douglas G. Gold ◽  
Keith M. Furutani ◽  
O. Kenneth Macdonald ◽  
Robert H. McLaren ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Dose Rate ◽  
High Dose Rate ◽  
Localized Prostate Cancer ◽  
Curative Treatment ◽  
High Dose ◽  
High Dose Rate Brachytherapy

scholarly journals Two-Weekly High-Dose-Rate Brachytherapy Boost After External Beam Radiotherapy for Localized Prostate Cancer: Long-Term Outcome and Toxicity Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Jörg Tamihardja ◽  
Paul Lutyj ◽  
Johannes Kraft ◽  
Dominik Lisowski ◽  
Stefan Weick ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Dose Rate ◽  
External Beam Radiotherapy ◽  
High Dose Rate ◽  
Localized Prostate Cancer ◽  
High Dose ◽  
High Dose Rate Brachytherapy ◽  
Brachytherapy Boost ◽  
Gi Toxicity

PurposeEvaluation of clinical outcome of two-weekly high-dose-rate brachytherapy boost after external beam radiotherapy (EBRT) for localized prostate cancer.Methods338 patients with localized prostate cancer receiving definitive EBRT followed by a two-weekly high-dose-rate brachytherapy boost (HDR-BT boost) in the period of 2002 to 2019 were analyzed. EBRT, delivered in 46 Gy (DMean) in conventional fractionation, was followed by two fractions HDR-BT boost with 9 Gy (D90%) two and four weeks after EBRT. Androgen deprivation therapy (ADT) was added in 176 (52.1%) patients. Genitourinary (GU)/gastrointestinal (GI) toxicity was evaluated utilizing the Common Toxicity Criteria for Adverse Events (version 5.0) and biochemical failure was defined according to the Phoenix definition.ResultsMedian follow-up was 101.8 months. 15 (4.4%)/115 (34.0%)/208 (61.5%) patients had low-/intermediate-/high-risk cancer according to the D`Amico risk classification. Estimated 5-year and 10-year biochemical relapse-free survival (bRFS) was 84.7% and 75.9% for all patients. The estimated 5-year bRFS was 93.3%, 93.4% and 79.5% for low-, intermediate- and high-risk disease, respectively. The estimated 10-year freedom from distant metastasis (FFM) and overall survival (OS) rates were 86.5% and 70.0%. Cumulative 5-year late GU toxicity and late GI toxicity grade ≥ 2 was observed in 19.3% and 5.0% of the patients, respectively. Cumulative 5-year late grade 3 GU/GI toxicity occurred in 3.6%/0.3%.ConclusionsTwo-weekly HDR-BT boost after EBRT for localized prostate cancer showed an excellent toxicity profile with low GU/GI toxicity rates and effective long-term biochemical control.

Sign in / Sign up

Export Citation Format

Share Document